Sinopharm's 2024 Attributable Profit Slides; Shares Fall 4%

MT Newswires Live

03-24

Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.

Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.67 yuan.

Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.

The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.

Shares slipped 4% during Monday's afternoon trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2521676848"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521676848\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521676848?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521676848","market":"nz","top_or_hot":-1,"title":"Sinopharm's 2024 Attributable Profit Slides; Shares Fall 4%","media":"MT Newswires Live","content":"<html><body><p> Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.</p><p>Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier.  Analysts at Visible Alpha estimated EPS at 2.67 yuan.</p><p>Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.</p><p>The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.</p><p>Shares slipped 4% during Monday's afternoon trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm's 2024 Attributable Profit Slides; Shares Fall 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm's 2024 Attributable Profit Slides; Shares Fall 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-24 14:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.</p><p>Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier.  Analysts at Visible Alpha estimated EPS at 2.67 yuan.</p><p>Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.</p><p>The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.</p><p>Shares slipped 4% during Monday's afternoon trading.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健護理產品經銷商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521676848","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521676848","pubTimestamp":1742796050,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sinopharm  attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier.  Analysts at Visible Alpha estimated EPS at 2.67 yuan.Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.Shares slipped 4% during Monday's afternoon trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1197":"保健护理产品经销商","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1515":"抗疫概念","BK1500":"做空集合股","01099":"国药控股"},"translate_title":"国药控股2024年归属利润下滑；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier.  Analysts at Visible Alpha estimated EPS at 2.67 yuan.Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.Shares slipped 4% during Monday's afternoon trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}